Table 1.

Outcome measures in the MONITOR-PsA cohort study

Procedures	Visits
	Baseline cohort
	Week 0	Week 12	Week 24	Week 36	Week 48	Week 72	Week 96	Annually (after 96 weeks)
Informed consent	X
Demographics	X
Medical history	X	X	X	X	X	X	X	X
Medications	X	X	X	X	X	X	X	X
Physical examination	X	X	X	X	X	X	X	X
Routine blood tests (FBC, U&Es, LFTs, CRP and eGFR)	X	X	X	X	X	X	X	X
Immunology (RF, ACPA, ANA)	X
Radiographs of hands/feet/spine	X				X		X	X
Eligibility assessment	X
Adherence		X	X	X	X	X	X	X
68/66 Joint count	X	X	X	X	X	X	X	X
Leeds and SPARCC enthesitis index	X	X	X	X	X	X	X	X
Dactylitis count	X	X	X	X	X	X	X	X
Psoriasis assessment (PASI and BSA)	X	X	X	X	X	X	X	X
Physician VAS	X	X	X	X	X	X	X	X
Metrology with BASMI (if axial involvement)	X				X		X	X
Patient questionnaires (VAS, HAQ, SF36, PsAID, WPAI, BASDAI, BASFI)	X	X	X	X	X	X	X	X
TSQM questionnaire		X	X	X	X	X	X	X
EQ-5D-5L questionnaire	X		X		X	X	X	X
Healthcare utilisation data			X		X	X	X	X
Adverse event assessments	X	X	X	X	X	X	X	X